Chuqi Lin

Chuqi Lin

Auto-generated profile, based on publicly available information

Chuqi Lin

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2024 in Cancer Discovery
Verified
Journal Article
Closed access
CZChaoqi Zhang
Chaoqi Zhang
PWPeng Wu
Peng Wu
DLDongyu Li
Dongyu Li
XGXuanyu Gu
Xuanyu Gu
CLChuqi Lin
Chuqi Lin
JHJie He
Jie He
Summary: The Chinese government has, in recent decades, implemented various administrative laws and regulatory policies to expedite cancer therapeutic development, boosting research and development pipelines for domestic pharmaceutical companies and clinical trials; however, China faces unique challenges given the high prevalence of certain cancer types and distinct disease burdens, some of which are frequently overlooked by international pharmaceutical companies. Given the substantial unmet need for China-specific cancer care, it is crucial to promote the development of innovative pharmaceutical and clinical research in China, with a particular emphasis on addressing tumors most prevalent in its population.

17 June 2026
Verified
Other
Open access
CZChaoqi Zhang
Chaoqi Zhang
PWPeng Wu
Peng Wu
DLDongyu Li
Dongyu Li
XGXuanyu Gu
Xuanyu Gu
CLChuqi Lin
Chuqi Lin
JHJie He
Jie He
Supplementary Table 5. The number of clinical trials evaluating Chinese domestic anti-cancer agents regarding different types of cancer from 2018-2023.

17 June 2026
Verified
Other
Open access
CZChaoqi Zhang
Chaoqi Zhang
PWPeng Wu
Peng Wu
DLDongyu Li
Dongyu Li
XGXuanyu Gu
Xuanyu Gu
CLChuqi Lin
Chuqi Lin
JHJie He
Jie He
Supplementary Table 3. The detailed information obtained from Pharmcube regarding the total number of first-in-class (FIC) anti-cancer agents.

1 November 2024
Verified
Other
Open access
CZChaoqi Zhang
Chaoqi Zhang
PWPeng Wu
Peng Wu
DLDongyu Li
Dongyu Li
XGXuanyu Gu
Xuanyu Gu
CLChuqi Lin
Chuqi Lin
JHJie He
Jie He
Supplementary Table 1. The number of Investigational New Drug (IND) and New Drug Application (NDA) applications retrieved from the Annual Drug Evaluation Report by the Center for Drug Evaluation (CDE) from 2018-2023.

1 November 2024
Verified
Other
Open access
CZChaoqi Zhang
Chaoqi Zhang
PWPeng Wu
Peng Wu
DLDongyu Li
Dongyu Li
XGXuanyu Gu
Xuanyu Gu
CLChuqi Lin
Chuqi Lin
JHJie He
Jie He
Supplementary Table 3. The detailed information obtained from Pharmcube regarding the total number of first-in-class (FIC) anti-cancer agents.

17 June 2026
Verified
Other
Open access
CZChaoqi Zhang
Chaoqi Zhang
PWPeng Wu
Peng Wu
DLDongyu Li
Dongyu Li
XGXuanyu Gu
Xuanyu Gu
CLChuqi Lin
Chuqi Lin
JHJie He
Jie He
Supplementary Table 4. The incidence rates, in terms of age-standardized rates (ASRs), of the top 20 cancer types in China and globally from the 2022 edition of data of the GLOBOCAN database.